Genomic Valley Biotech P/E Ratio
Current P/E Ratio
22.79
Moderate Valuation
High - Growth expectations or overvalued
Genomic Valley Biotech (GVBL) P/E ratio is 22.79 (Moderate), EPS (TTM) ₹1.17, current price ₹26.67 on BSE — High - Growth expectations or overvalued. For live price, revenue and the complete fundamental profile, see GVBL screener.
Current Valuation Metrics
P/E Ratio
22.79
Current Price
₹26.67
EPS (TTM)
₹1.17
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
49.88
Sector Median
29.34
Sector Rank
#11 of 191
Sector Percentile
5.8%
GVBL P/E Ratio — Valuation Signal & Historical Context
Genomic Valley Biotech P/E 22.79 — signal: Overvalued. Analyse GVBL shareholding pattern to track promoter, FII and institutional holdings.
- Trading at discount to sector average PE of 49.88
GVBL vs Healthcare Peers — P/E Ratio Comparison
Genomic Valley Biotech P/E 22.79 vs Healthcare average 49.88, median 29.34 — range 1.0–869.57.
Sector Average
49.88
Sector Median
29.34
Lowest P/E
1.0
Highest P/E
869.57
Companies
191
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.0 | ₹36 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.45 | ₹61 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.69 | ₹1,161 | Low |
| Amwill Health Care | AMWILL | 6.34 | ₹65 | Low |
| Brooks Laboratories | BROOKS | 6.6 | ₹137 | Low |
| Mono Pharmacare | MONOPHARMA | 7.1 | ₹21 | Low |
| Shelter Pharma | SHELTER | 7.4 | ₹54 | Low |
| Medicamen Organics | MEDIORG | 7.51 | ₹32 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹66 | Low |